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Abstract—The aim of this work is to present a machine 
learning based method for the prediction of adverse events 
(mortality and relapses) in patients with heart failure (HF) 
by exploiting, for the first time, measurements of breath and 
saliva biomarkers (Tumor Necrosis Factor Alpha, Cortisol 
and Acetone).  Data from 27 patients are used in the study 
and the prediction of adverse events is achieved with high 
accuracy (77%) using the Rotation Forest algorithm.  As in 
the near future, biomarkers can be measured at home, 
together with other physiological data, the accurate 
prediction of adverse events on the basis of home based 
measurements can revolutionize HF management.  
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I.  INTRODUCTION  
Heart failure (HF) is a chronic life-threatening condition 
characterized by high rates of mortality and re-
hospitalizations.  The European Society of Cardiology 
reports that 26 million people worldwide suffer from HF and 
74% of them present at least one comorbidity [1].  HF is 
characterized by frequent re-admissions to hospital. HF 
accounts for 1-3% of all hospital admissions, while almost 
the 24% of hospitalized patients are re-hospitalized within a 
30-day and the 46% within a 60-day, post discharge period.  
Across the world, the 2-17% of patients admitted to hospital 
with HF die while in hospital and the 17-25% die within one 
year of admission [2].  The cost of HF management is driven 
by hospitalizations, corresponding to 1-2% of total 
healthcare expenditure. 
The ability to accurately predict the aforementioned 
undesirable events enables the effective risk stratification of 
patients and allows the clinical decision making. This 
valuable prognostic information can guide the clinical 
experts in the adaptation of patient management and in the 
selection of the best treatment plan that should be followed. 
In turn, this is expected to improve the quality of care 
provided to the patients, while in parallel result in better 
health outcomes. Towards this direction, different factors 
have been studied for their predictive ability in HF morbidity 
and mortality, destabilizations and re-hospitalizations. In 
addition, several studies have been conducted focusing on 
the simultaneous examination of multiple factors using 
statistical methods (e.g. multi-variable Cox regression 
models). Such studies resulted in the creation of 
acknowledged in the clinical practice scores: (i) for the 
estimation of risk for mortality, the Heart Failure Survival 
Score [3], the Get With the guidelines score [4], the Seattle 
Heart Failure Model [5], the EFFECT [6], (ii) for re-
hospitalizations [7], and (iii) for morbidity [8]. 
The prediction of re-hospitalizations [9-15] and mortality 
[11], [16-23]  has gained the interest of researchers who 
developed prediction models exploiting different categories 
of information (e.g. sociodemographic, clinical examination, 
medical condition, lab tests, medication intake, phenotypic 
data, sensor data) along with machine learning techniques.  
A description of the methods reported in the literature and a 
comparison of them are presented in [24]. 
Recent research has identified certain biomarkers which 
strongly correlate with the HF severity, progression and 
mortality [25-42].  Moreover, progress in analytical 
chemistry and biosensor development allows some of them 
to be detected in saliva and breath [43-46].  Uric Acid, 
Tumor Necrosis Factor Alpha (TNF-a), a-Amylase, Lactate, 
Cortisol and 8-iso-prostaglandin F2a, are among the most 
important saliva biomarkers, while Acetone (2-Propanon) 
and 2-methy-1,3-butadiene (isoprene) are indicative 
examples of breath biomarkers that play a key role in the 
patient diagnosis and prognosis. 
The goal of this study is to introduce such biomarkers in 
the adverse event prediction process.  Obtaining saliva and 
breath biomarkers is non – invasive and in a future setting 
can be performed at home [47], becoming on this way a 
significant tool for HF patient management. In our study, 
we employ these breath and saliva biomarkers in a machine 
learning approach which combines heterogeneous patient 
data (i.e. sociodemographic, clinical, sensor data and 
biomarkers) for the prediction of adverse events. 
II. MATERIALS AND METHODS 
A. Dataset 
The proposed method is evaluated using a dataset of 27 
patients collected by the clinical center of the Universita Di 
Pisa (UNIPI), Italy within the framework of the HEARTEN 
project [47].  The criteria for patient selection are reported in 
Table I.   
TABLE I.  CRITERIA FOR PATIENT ENROLLMENT. 
Criteria Patients 
I diagnosed with HF (Framingham criteria) who have continuous symptoms with frequent recurrence 
II belonging to the functional NYHA I-IV class followed by an optimal treatment 
III recently hospitalized, (at least one in the last six months) 
IV undergone one electrocardiogram (in the last 12 months) and have HF symptoms 
V underage, with very severe HF, patients with obesity and advanced chronic kidney failure are not included 
 
The features recorded for each patient can be grouped to 
the following categories (Table II). 
TABLE II.  FEATURES RECORED FOR EACH PATIENT. 
Category Description 
General 
information 
Age, gender, existence/relation with caregiver, 
education level, ethnicity etc.. 
Allergies Features expressing the presence or not of allergies 
Category Description 
and a feature indicating the presence or not of drug 
side effects. 
Medical 
Condition 
Experts annotation in terms of the NYHA class, 
smoking habit, alcoholism habit of the patient, as 
well as, the presence or not of comorbidities. 
Drugs Active substance, dose and frequency of intake. 
Biological data 
Height, Temperature, Systolic pressure, Diastolic 
pressure, Heart Rate, LDLc, HDLc, Glucose , 
triglycerides, Calcium, Sodium, Potassium, 
Natriuretic peptides, Hemoglobin A1c, 
Hemoglobin, International normalized ratio, 
Hematocrit, White Blood Cells, SGOT/SGPT, 
Oxygen saturation in Capillary blood by Oximetry, 
Partial pressure of oxygen, Partial pressure of 
carbonic, Cardiac troponin I, Cardiac troponin T, 
Creatinine, Microalbumin [Mass/volume] in Urine, 
C-reactive protein (CRP), Creatine kinase 
[Enzymatic activity/volume] in Serum or Plasma, 
Blood Urea Nitrogen, Urea, GFR/eGFR, Uric Acid , 
Iron binding capacity [Mass/volume] in Serum or 
Plasma, Iron [Mass/volume] in Serum or Plasma, 
Thyrotropin (TSH), Thyroxine (free T4), Thyroxine 
(free T3) 
Clinical 
Examinations 
Left bundle branch block or intraventricular delay, 
left ventricular ejection fraction, etc. 
Adherence 
Experts estimation regarding adherence of patients 
in terms of medication, activity, and nutrition and 
the prediction of the medication adherence risk of 
the patient which is extracted by the Adherence risk 
module of the HEARTEN project. 
Score 
Five scores are computed; European Heart Failure 
Self-care Behavior Scale 12-item scale for 
evaluating HF self-care [48], [49], Heart Failure 
Knowledge score that is related to HF knowledge in 
general, knowledge on HF treatment, symptoms 
recognition and occurrence [50], Get with the 
guidelines for estimating the in-hospital mortality 
[51], Seattle Heart Failure Model for predicting the 
1-, 2-, and 3-year survival of HF patients [5], 
Minnesota Living with Heart Failure for providing 
feedback regarding the physical and emotional 
status of the HF patient [52]. 
Sensor data 
Time and frequency domain Heart Rate Variability 
features extracted from the electrocardiogram 
(ECG), as well as respiration rate, weight and 
activity related data. 
Biomarkers Concentration of Tumor Necrosis Factor Alpha (TNF-a), Cortisol and Acetone (2-Propanon). 
 
Based on clinical studies on biomarker behavior and 
influence, performed during the HEARTEN project, the 
following biomarkers are selected as most prominent marker 
compounds for monitoring HF conditions: (i) acetone in 
breath, (ii) cortisol and TNF-a in saliva.  More specifically, 
acetone mirrors metabolism, as well as metabolic stress and 
the concentrations of acetone are elevated in HF patients 
compared to healthy subjects.  A very significant increase in 
salivary cortisol levels is observed in peculiar cases when a 
sudden worsening of patients happened during 
hospitalization. In HEARTEN studies, after therapy 
adjustment, the cortisol decreased by a factor of about 2.  As 
a consequence, cortisol was considered a good candidate for 
monitoring the HF patients.  Additionally, chronic HF  
  
Figure 1.  Schematic representation of the proposed method. 
 
patients have shown high circulating levels of TNF-a, which 
correlate with the severity of their disease, since TNF-a 
levels show a linear relation with HF prognosis.  Moreover, 
several studies have demonstrated that concentrations of 
TNF-a in saliva may reflect those in serum, making the TNF-
a an ideal HF-related salivary biomarker. 
In total, 263 features are recorded for each patient (3 
features corresponding to biomarkers, 151 features extracted 
from sensor data and 109 features corresponding to the other 
categories). 
These features are recorded from the first time of 
patient’s hospitalization until discharge, every second day.  
Thus, 141 instances are collected from all patients.  It must 
be mentioned that the number of the hospitalizations days is 
not the same for all patients.  On average, each stay lasts 
approximately 4 days.  The dataset given as input to the 
proposed method is created with the assumption that the 
discharge instance of each patient is considered as event free 
(“no event” class), while the instance of the patient when the 
event was presented and/or the first hospitalization took 
place is considered as event (“event” class).  This results to a 
set of 54 instances, with 25 corresponding to an event and 29 
to a no event. 
B. The proposed method 
The proposed method consists of three steps: (i) 
preprocessing, (ii) feature selection, (iii) classification.  A 
schematic representation of the proposed method is shown in 
Fig. 1 and a detailed description of each stage is provided 
below. 
In the first step, missing values are addressed.  Features 
with more than 60% of missing values are removed, since 
imputation of missing values cannot be performed due to the 
nature of the data.  Furthermore, features where the 
distribution between the values is greater than 80% are not 
retained.  In the second step, the identification of features 
that can act as discriminators between the two expected 
situations (presence of an event or not) are selected 
following a wrapper approach [53], in combination with the 
classifiers employed in step 3.  Two different approaches are 
tested.  The first one (Fig. 1i) takes as input all the features, 
while in the second (Fig. 1ii), the method is applied 
separately to features extracted from sensor data and to 
features corresponding to categories (i)-(vii).  Finally, in the 
third step, nine classifiers are employed and tested [54]: (i) 
Random Forests (RF), (ii) Logistic Model Trees (LMT), (iii) 
J48, (iv) Rotation Forest (ROT), (v) SVM, (vi) Radial Basis 
Function Network (RBF Network), (vii) Bayesian Network 
(BN), (viii) Naïve Bayes (NB), (ix) Simple Classification 
and Regression Tree (Simple CART). 
III. RESULTS 
The proposed method is evaluated on a dataset of 54 
instances, while the number of features is differentiated 
depending on the outcome of the feature selection step.  The 
obtained results in terms of accuracy (Acc), sensitivity 
(Sens), specificity (Spec) and area under curve (AUC) are 
presented in Table III.  Both approaches produce rather 
similar results (accuracy 76% and 77%, respectively), with 
12 features to be finally selected in the first apporach and 23 
features in the second approach.  Rotation Forests (ROT) 
seem to be the best performing classification algorithm (see 
Table IV). 
In order to evaluate the contribution of biomarkers in the 
prediction of adverse events, the following experiments are 
made: (i) all available features are given as input, (ii) features 
only from sensors are employed, (iii) features only from 
biosensors are utilized as predictors, and (iv) features from 
sensors and biosensors are met.  The results without feature 
selection are presented in Table V.  The results 
TABLE III.  RESULTS OF THE PROPOSED METHOD. 
Classifiers 
Evaluation measures 
Acc Sens Spec AUC 
1st approach of feature selection approach 
NB 76% 76% 76% 76% 
Classifiers 
Evaluation measures 
Acc Sens Spec AUC 
2nd approach of feature selection approach 
ROT 77% 77% 77% 74% 
TABLE IV.  EVENT PREDICTION RESULTS PER CLASSIFIER FOLLOWING THE 
SECOND APPROACH 
Classifiers 
BN NB RBF SVM ROT J48 LMT RF CART 
37% 58% 60% 56% 77% 53% 58% 60% 58% 
TABLE V.  EVENT PREDICTION TESULTS ON DIFFERENT COMBINATIONS 
OF FEATURES (WITHOUT FEATURE SELECTION). 
Case Model Acc 
(i) All features without feature 
selection ROT 57% 
(ii) Features only from sensors 
without feature selection RF 60% 
(iii) Features only from 
biosensors without feature 
selection 
CART 66% 
(iv) Features from sensors and 
biosensors  without feature 
selection 
ROT 59% 
TABLE VI.  EVENT PREDICTION RESULTS ON DIFFERENT COMBINATION 
OF FEATURES (USING FEATURE SELECTION). 
Case Model Acc 
(i) All features with feature 
selection NB 76% 
(ii) Features only from sensors  
with feature selection RF 71% 
(iii) Features only from 
biosensors with feature selection CART 66% 
(iv) Features from sensors and 
biosensors with feature selection RF 72% 
The proposed method ROT 77% 
 
presented in Table VI are extracted from the same 
experiments, as those presented in Table V, but this time 
following feature selection. 
It should be noted that in case (iii) where only biomarkers 
are utilized, the feature selection approach is not applied due 
to the already small number of biomarkers used (i.e. three).  
As shown in Tables V and VI, our approach yields superior 
results. The positive effect of feature selection is also clear 
(accuracy improvement from 66% to 77%). 
A comparison of the proposed method with those reported 
in the literature (Table VII) cannot be directly performed 
since the studies reported in the literature: (i) predict the 
presence or not of one specific adverse event only 
(destabilizations, re-hospitalizations, mortality) and not the 
presence or not of HF adverse event in general like the 
proposed method, and (ii) do not utilize biomarkers.  
Focusing on specific adverse events, of course it has 
advantages for clinical practice; still it requires a much larger 
dataset.  In this sense, this can be considered as a limitation 
of the proposed method.  This will be addressed in the future 
through the data that will be collected during the pilot phase 
of the HEARTEN project.  The utilization of breath and 
saliva biomarkers is the innovative feature of the proposed 
method. 
TABLE VII.  COMPARISON WITH THE LITERATURE. 
Study* Evaluation measures 
Destabilizations 
Candelieri et al. 2008  Acc 92.03% 
Candelieri et al. 2009  Acc 82.06% 
Candelieri et al. 2010  Acc 87.35% 
Guidi et al. 2014  Acc 87.60% 
Guidi et al. 2015  Acc 71.90% 
Re-hospitalizations 
Zolfaghar et al. 2013  Acc 87.12% 
Vedomske et al. 2013  AUC 84.00% 
Koulaouzidis et al. 2016  AUC 82.00% 
Kang et al. 2016  AUC (c-statistic) 59.00% 
Tugerman et al. 2016 AUC 84.20% 
Mortality 
Shah et al. 2015 AUC 71.80% 
Fonarrow et al. 2005 odds ratio for mortality  12.9 
Bohacik et al. 2013  Acc 77.66% 
Panahiazar et al. 2015  
1-year AUC 68.00% (baseline set) 81.00% (extended set) 
2-years AUC: 70.00% (baseline set) 74.00% (extended set) 
5-years AUC 61.00% (baseline set) 73.00% (extended set) 
Taslimitehrani et al. 
2016  
1-year Acc   91.40% 
2-years Acc 83.00% 
5-years Acc 80.90% 
Austin et al. 2012  AUC 79.00% 
Bochacik et al. 2015  
Sens 63.27% 
Spec 65.54% 
Ramirez et al. 2015  
Sudden Cardiac Death 
Sens 
Spec 
18.00% 
79.00% 
Pump Failure Death 
Sens 
Spec 
14.00% 
81.00% 
Subramanian et al. 2011  AUC(c-statistic)  84.00% 
Prediction of adverse events 
Proposed method with 
biomarkers 
Acc 77.00% 
AUC 74.00% 
* Studies references are presented in reference [24] of the current study. 
IV. CONCLUSIONS 
An automated method for the prediction of adverse events 
related to HF, utilizing information from saliva and breath 
biomarkers, is presented.  Different experiments are 
conducted in order the proposed method to be evaluated and 
the contribution of biomarkers to the prediction problem to 
be estimated.  The results confirm the prediction ability of 
biomarkers either if they are employed as the only input 
(Acc: 66%) or in combination with other categories of 
features (Acc: 77%).  Among the biomarkers, TNF-a is the 
one that presents the largest correlation with the prediction 
of an adverse event.  However, the small number of 
instances does not allow the extraction of “safe” 
conclusions.  The collection of biomarkers measurements 
from a larger number of patients will lead to a more in-depth 
evaluation. 
As in the near future biomarkers can be measured at 
home, together with biosensor data, the accurate prediction 
of adverse events on the basis of home based measurements 
will revolutionize HF patient management. Such an 
approach can become the core of a chronic care model, 
allowing for early action by both, patients and physicians. 
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